Moreover, CD4+ T cells from long-term survivor patients post-TAPCells therapy have significantly higher expression levels of cell surface CLEC2D than CD4+ T cells isolated from the peripheral blood of HD. The gene discussed is CD4; the disease is Huntington disease.